Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are medications that help to relax the airway muscles and improve breathing. In Senegal, the market for bronchodilator drugs has been experiencing notable growth in recent years.
Customer preferences: Customers in Senegal are increasingly seeking bronchodilator drugs due to the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, the affordability of these drugs has made them more accessible to the general population.
Trends in the market: The market for bronchodilator drugs in Senegal has been growing steadily due to several factors. Firstly, the increasing prevalence of respiratory diseases has led to an increased demand for these drugs. Secondly, the government has been investing in improving healthcare infrastructure, which has led to better access to healthcare facilities and medications. Finally, the entry of new players in the market has increased competition, leading to lower prices and increased availability of bronchodilator drugs.
Local special circumstances: Senegal has a large population of young people, and the prevalence of respiratory diseases in this age group is increasing. This has led to a growing demand for bronchodilator drugs that are safe for use in children. Additionally, due to the high levels of poverty in the country, many people cannot afford expensive medications. This has led to a preference for cheaper, generic versions of bronchodilator drugs.
Underlying macroeconomic factors: The Senegalese economy has been growing steadily in recent years, with a focus on developing the healthcare sector. The government has been investing in improving healthcare infrastructure, which has led to better access to healthcare facilities and medications. Additionally, the country has a young population, which has led to an increased demand for healthcare services. These factors have contributed to the growth of the bronchodilator drugs market in Senegal.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
